fenofibric acid has been researched along with pioglitazone in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Albrektsen, T; Bury, PS; Deussen, HJ; Din, N; Fleckner, J; Frederiksen, KS; Jeppesen, L; Mogensen, JP; Nehlin, J; Pettersson, I; Sauerberg, P; Svensson, LA; Wulff, EM; Ynddal, L | 1 |
| Iwai, K; Kitoh, M; Maruta, K; Nagamine, J; Nagata, R; Taiji, M; Tsuchida, A; Ushiroda, K | 1 |
| Horai, S; Kohno, T; Maruta, K; Nagano, T; Nagata, R; Sato, Y; Taiji, M; Takazawa, T; Ushiroda, K; Yanagi, K | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Buechler, C; Kirchner, S; Laberer, S; Neumeier, M; Schäffler, A; Schölmerich, J; Weigert, J; Weiss, T | 1 |
| Benz, J; Dietz, M; Grether, U; Hartman, P; Kuhn, B; Maerki, HP; Mohr, P; Ruf, A; Wright, MB | 1 |
2 review(s) available for fenofibric acid and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
5 other study(ies) available for fenofibric acid and pioglitazone
| Article | Year |
|---|---|
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
Topics: Alkenes; Amino Acid Sequence; Animals; Binding Sites; Biological Availability; Cell Line; Crystallography, X-Ray; Dimerization; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Sequence Data; Propionates; Rats; Receptors, Cytoplasmic and Nuclear; Sequence Alignment; Stereoisomerism; Transcription Factors; Transcriptional Activation | 2003 |
Development of a new class of benzoylpyrrole-based PPARα/γ activators.
Topics: Acetates; Animals; Carboxylic Acids; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Mice, Obese; Obesity; PPAR alpha; PPAR gamma; Pyrroles; Rats; Structure-Activity Relationship | 2011 |
Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators.
Topics: Animals; Azoles; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Mice; Models, Animal; Models, Molecular; PPAR alpha; PPAR gamma | 2011 |
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
Topics: Adiponectin; Alitretinoin; Animals; Caco-2 Cells; Cell Line; CHO Cells; Chromans; Cricetinae; DNA-Binding Proteins; Fenofibrate; HeLa Cells; Hepatocytes; Humans; Hydroxycholesterols; Liver X Receptors; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR alpha; Receptors, Adiponectin; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; Thiazolidinediones; Tretinoin; Troglitazone; Up-Regulation | 2005 |
Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Fenofibrate; Ligands; Molecular Sequence Data; Oxazoles; Peptides; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Transcription, Genetic | 2012 |